Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,471 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07152340RecruitingPhase 4
Sequential hormone and IBI311 therapy for active TAO
This trial tests a two-step treatment for active, moderate-to-severe thyroid eye disease (TAO). You will first receive hormone therapy, followed by a drug called IBI311. The goal is to see if this sequence works better for people who have not had steroid treatment before.
Changhua, Shanghai MunicipalityAges 18–80 - NCT05456893Recruiting
Testing blood and stool markers in active ulcerative colitis treatments
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
Nancy, LorraineAges 18 years+ - NCT07137598RecruitingPhase 2
A study of RO7790121 for moderate to severe rheumatoid arthritis
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
Peoria, ArizonaAges 18 years+ - NCT07136116Recruiting
Study of risankizumab for moderate to severe ulcerative colitis in Japan
This study looks at how well risankizumab (an injected medicine) works for people with moderate to severe ulcerative colitis. It tracks your symptoms using a mobile app to see if the drug helps control the disease.
Nagakute, Aichi-kenAges 15 years+ - NCT07144111RecruitingPhase 1
Liver Function and Inavolisib Study
This study tests how the body processes the drug inavolisib when taken by people with moderate or severe liver problems compared to those with healthy livers. It helps doctors understand the right dose for patients with liver impairment.
Lake Forest, CaliforniaAges 18–80 - NCT07132112RecruitingEarly Phase 1
GT719 injection for moderate to severe autoimmune disease
This trial tests an experimental cell therapy (GT719) for people with autoimmune diseases like lupus, inflammatory myositis, or systemic sclerosis that have not responded well to other treatments. It aims to see if this therapy can help control the disease.
Nantong, JiangsuAges 18–65 - NCT07129382RecruitingPhase 1/Phase 2
Study of CS32582 for moderate to severe plaque psoriasis
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
Beijing, Beijing MunicipalityAges 18–70 - NCT07130604RecruitingPhase 3
Testing a new pill for moderate to severe plaque psoriasis
This trial tests an experimental pill called D-2570 for people with moderate to severe plaque psoriasis. It aims to see if the pill can safely improve skin symptoms like redness, scaling, and thickness.
Beijing, Beijing MunicipalityAges 18–70 - NCT07131410Enrolling by invitation
Hyaluronic acid cream to prevent foot ulcers in diabetes
This trial tests a cream made with hyaluronic acid, a natural substance that helps keep skin moist, to see if it can prevent foot sores in people with type 2 diabetes and nerve damage in their feet. If you have diabetes-related nerve issues and want to protect your feet, this study may be for you.
MálagaAges 18 years+ - NCT07122076RecruitingEarly Phase 1
GT719 injection for moderate to severe autoimmune diseases
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
ShanghaiAges 18–65 - NCT06964269RecruitingPhase 4
Acthar Gel for dry eye and autoimmune disease
This trial tests a new injectable medicine, Acthar Gel, for moderate to severe dry eye and eye pain linked to autoimmune disease. It aims to see if the drug can relieve these symptoms safely.
Nashville, TennesseeAges 18–85 - NCT07109765Recruiting
Secukinumab for moderate to severe hidradenitis suppurativa
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07087353Recruiting
Remote monitoring for moderate to severe depression
This study tests whether checking in with a mental health team remotely (using your phone) can help people with moderate to severe depression feel better. It’s designed for people who are already getting treatment and want extra support from home.
BesançonAges 18 years+ - NCT06453317RecruitingPhase 2
Comparing UC treatments: infliximab vs ustekinumab vs both
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
LodzAges 18–64 - NCT07078994RecruitingPhase 2
Study of a new drug for moderate to severe Crohn's disease
This trial tests a new medicine called BCD-261 for people with moderate to severe Crohn's disease that has not responded well to other treatments. It aims to see if the drug can reduce symptoms and inflammation.
Barnaul, Altayskiy KrayAges 18–75 - NCT07082738RecruitingPhase 2
Study of AZD6793 for people with moderate to very severe COPD
This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.
Birmingham, AlabamaAges 40 years+ - NCT07080034RecruitingPhase 2
Testing BCD-261 for moderate to severe ulcerative colitis
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
Barnaul, Altayskiy KrayAges 18–75 - NCT07083193RecruitingPhase 1/Phase 2
Study of AC-101 tablets for moderate to severe ulcerative colitis
This trial tests a new tablet called AC-101 for people with active moderate to severe ulcerative colitis. It aims to see if the drug can reduce symptoms like diarrhea and bleeding and help the gut heal.
Guangzhou, GuangdongAges 18–75 - NCT07069829Recruiting
Living with COPD: A study on Breztri/Trixeo
This study looks at how well a triple-combination inhaler called Breztri/Trixeo works for people with moderate to severe COPD. If you have been prescribed this inhaler but haven't started it yet, and you are between 30 and 80 years old, you may be able to join.
Buenos AiresAges 30–80 - NCT06747260RecruitingEarly Phase 1
Breast milk through the nose for HIE
This trial tests whether giving fresh breast milk through the nose is safe and possible for newborns with HIE (a brain injury from oxygen loss at birth) who are already receiving cooling therapy. It may help protect the brain and reduce injury.
BudapestAges Up to 2 days - NCT06987292Recruiting
Studying IL-17 inhibitors for hidden tendon inflammation in psoriasis
This study tests whether IL-17 inhibitor medications can reduce inflammation in tendons and ligaments that is not visible on the skin but can be detected with a special ultrasound. It may be an option for people with moderate to severe psoriasis who have not had enough relief from creams or light therapy.
Nanjing, JiangsuAges 18 years+ - NCT07056673Recruiting
Cold plasma for moderate to severe acne
This study tests whether a treatment called 'cold atmospheric plasma' (similar to a gentle, cool gas) can improve moderate-to-severe acne. It might offer a new, drug-free option for people with many pimples or cysts.
Luoyang, HenanAges 18–40 - NCT07056660Recruiting
Cold plasma for athlete's foot
This trial tests a new device that uses cold plasma (a gas with charged particles) to treat moderate-to-severe athlete's foot. It may be an option if standard creams haven't worked or you want to try a non-medication approach.
Luoyang, HenanAges 18–70 - NCT07037901RecruitingPhase 2
Testing IMG-007 for moderate-to-severe eczema
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
Lancaster, CaliforniaAges 18–74
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,471 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.